Lexpos News

Yesterday, Community Pharmacy England joined with the British Dental Association, British Medical Association, Optometric Fees Negotiating Committee and the Association for Primary Care Audiology Providers, to host the “From Crisis to Recovery” The Future of Primary Care parliamentary event. MPs had the opportunity to learn more about primary care services and the professionals who provide [...]

The post From Crisis to Recovery: CPE joins forces with primary care bodies to fight for a secure financial future appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 February 2026. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution [...]

The post Drug Tariff Watch – February 2026 appeared first on Community Pharmacy England.

In response to the government announcement that all pubs and live music venues will benefit from a 15% business rates relief, with bills also being frozen in real terms for a further two years, we have released the following statement to the press: Our CEO Janet Morrison said: “Unlike GP practices and dental surgeries, the [...]

The post Pharmacies deserve better – end the unfair disparity in business rates relief appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Arixtra solution for injection pre-filled syringes (Viatris Products Ltd) Drug alert number: EL(26)A/04 Date issued: 28 January 2026 Viatris has received reports of brown discolouration and blockage in the needle of pre-filled syringes of Arixtra. This quality defect is related to oxidation of the syringe needle. DMRC reference number:DMRC-38220370 Marketing [...]

The post MHRA Class 4 Medicines Defect Notification: Arixtra solution for injection pre-filled syringes (Viatris Products Ltd) appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches. MSN/2026/004 Tier 2 – Medium impact Date of issue: 28 January 2026 Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches are out of stock until late-February 2026. Oxybutynin 5mg and 10mg modified-release tablets remain available and can support increased [...]

The post Medicine Supply Notification: Oxybutynin (Kentera® ) 3.9mg/24hours transdermal patches appeared first on Community Pharmacy England.